A phase I COVID-19 vaccine trial among SARS-CoV-2 seronegative and seropositive individuals in Uganda utilizing a self-amplifying RNA vaccine platform: Screening and enrollment experiences

We report the screening and enrollment process for a phase I vaccine trial in Masaka, Uganda that investigated the safety and immunogenicity of a self-amplifying SARS-CoV-2 RNA vaccine amongst individuals with and without antibodies to SARS-CoV-2. Participant screening and enrollment were conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitonsa, Jonathan, Kamacooko, Onesmus, Ruzagira, Eugene, Nambaziira, Florence, Abaasa, Andrew, Serwanga, Jennifer, Gombe, Ben, Lunkuse, Jane, Naluyinda, Hadijah, Tukamwesiga, Naboth, Namata, Tamara, Kigozi, Antony, Kafeero, Paddy, Basajja, Vincent, Joseph, Sarah, Pierce, Benjamin F., Shattock, Robin, Kaleebu, Pontiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Coronavirus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411305/
https://www.ncbi.nlm.nih.gov/pubmed/37553178
http://dx.doi.org/10.1080/21645515.2023.2240690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10411305/
https://www.ncbi.nlm.nih.gov/pubmed/37553178
http://dx.doi.org/10.1080/21645515.2023.2240690

Ejemplares similares